Review Artikel: Memperbaiki Permeabilitas Obat Bcs Kelas II, III Dan IV Dengan Metode Ko-Amorf
Bilah Samping Artikel
Isi Artikel Utama
Page: 307-314
Abstrak
Obat dalam bentuk ko-amorf adalah kombinasi obat amorf dengan ko-former yang mempunyai kelarutan dan stabilitas yang baik sehingga disolusi menjadi lebih baik dan berpengaruh ke efek terapetik obat menjadi lebih baik juga. Pertama kali formulasi ko-amorf dibuat untuk mengatasi sifat kelarutan yang rendah pada BCS kelas II. Namun, penelitian saat ini menemukan bahwa formulasi ko-amorf tidak hanya dapat memperbaiki kelarutan saja tetapi juga dapat memperbaiki permeabilitas dari obat BCS kelas III dan IV. Metode pembuatan ko-amorf antara lain adalah cryomilling, melting and quench cooling, solvent evaporation, dan spray drying. Review artikel ini dilakukan untuk mengumpulkan informasi tentang obat BCS kelas II, III, dan IV yang dibuat dalam bentuk ko-amorf sehingga sifat fisikokimia obat seperti kelarutan, permeabilitas, dan stabilitas menjadi lebih baik. Artikel dikumpulkan dari 20 jurnal penelitian yang diterbitkan selama 10 tahun terakhir. Hasil pengujian obat ko-amorf dari 10 obat menunjukkan kelarutan dan permeabilitas yang lebih tinggi daripada dalam bentuk kristal.
Unduhan
Rincian Artikel
Artikel ini berlisensiCreative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Referensi
Aulton, M.E., dan Kelvin, M.G.T. 2018. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. 5th Edition. UK: Elsevier.
Chavan RB, Thipparaboina R, Kumar D, Shastri NR. 2016. Co amorphous systems: A product development perspective. Int J Pharm. 515(1-2):403-415.
Chen X, Li D, Zhang H, Duan Y, Huang Y. 2021. Co-amorphous systems of sinomenine with nonsteroidal anti-inflammatory drugs: A strategy for solubility improvement, sustained release, and drug combination therapy against rheumatoid arthritis. Int J Pharm. 606:120894.
China Pharmaceutical University. 2013. A simvastatin-gliclazide co-amorphous compound. Available from: https://patents.google.com/patent/CN103360357A/en
China Pharmaceutical University. 2013. Carvedilol-asccharin amorphous compound. Available from: https://patents.google.com/patent/CN103467363A/en
China Pharmaceutical University. 2013. Irbesartan and repaglinide co-amorphous substance. Available from: https://patents.google.com/patent/CN103497178A/en?oq=CN103497178A
Dengale SJ, Grohganz H, Rades T, Löbmann K. 2016. Recent advances in co-amorphous drug formulations. Adv Drug Deliv Rev. 100:116-25.
Hatanaka, Y., Uchiyama, H., Kadota, K., & Tozuka, Y. 2021. Improved solubility and permeability of both nifedipine and ketoconazole based on coamorphous formation with simultaneous dissolution behavior. Journal of Drug Delivery Science and Technology. 65: 102715.
Hebei Medical University. 2015. Azelnidipine-maleic acid co-amorphous substance and preparation method. Available from: https://patents.google.com/patent/CN104693181A/en
Hirakawa, Y., Hiroshi Ueda, Tetsuya Miyano, Noriho Kamiya, Masahiro Goto. 2019. New insight into transdermal drug delivery with supersaturated formulation based on co-amorphous system. International Journal of Pharmaceutics. 569: 118582.
Jana, S., dan Subrata, J. 2017. Particulate Technology for Delivery of Therapeutics. Singapore: Springer.
Jensen KT, Larsen FH, Löbmann K, Rades T, Grohganz H. 2016. Influence of variation in molar ratio on co-amorphous drug-amino acid systems. Eur J Pharm Biopharm. 107:32-9.
Karagianni, A., Kachrimanis, K., Nikolakakis, I. 2018. Co-amorphous solid dispersions for solubility and absorption improvement of drugs: composition, preparation, characterization and formulations for oral delivery. Pharmaceutics. 10(3):98.
Korhonen, Ossi., Pajula, K., Laitinen, R. 2016. Rational excipient selection for co-amorphous formulations. Expert Opinion on Drug Delivery. 14(4):551-569.
Laitinen R, Löbmann K, Strachan CJ, Grohganz H, Rades T. 2013. Emerging trends in the stabilization of amorphous drugs. Int J Pharm. 453(1):65-79.
Löbmann K, Laitinen R, Grohganz H, Strachan C, Rades T, Gordon KC. 2013. A theoretical and spectroscopic study of co-amorphous naproxen and indomethacin. Int J Pharm. 453(1):80-7.
MIMS. 2022. MIMS. Available from: https://www.mims.com/indonesia
Mizoguchi R, Waraya H, Hirakura Y. 2019. Application of co-amorphous technology for improving the physicochemical properties of amorphous formulations. Mol Pharm. 16(5):2142-2152.
Prajapati, B., Indrani Maji, Rahul Kumar, Devendrasingh Tomar, Dharmendra Kumar Khatri, Jitender Madan, Pankaj Kumar Singh. 2022. Strategy to counteract the pyrazinamide induced hepatotoxicity by developing naringin based co-amorphous system with supplementary benefits. Journal of Drug Delivery Science and Technology. 69: 103181.
Ruponen M, Kettunen K, Santiago Pires M, Laitinen R. 2021. Co-amorphous formulations of furosemide with arginine and p-glycoprotein inhibitor drugs. Pharmaceutics. 13(2):171.
Ruponen, M., Henna, R., dan Riikka, L. 2020. Dissolution and permeability properties of co-amorphous formulations of hydrochlorothiazide. Journal of Pharmaceutical Sciences. 109(7).
Setyawan, D., dan Diajeng, P. P. 2020. Strategi Peningkatan Kelarutan Bahan Aktif Farmasi. Surabaya: Airlangga University Press.
Sormunen H, Ruponen M, Laitinen R. 2019. The effect of co-amorphization of glibenclamide on its dissolution properties and permeability through an MDCKII-MDR1 cell layer. Int J Pharm. 570:118653.
Teja A, Musmade PB, Khade AB, Dengale SJ. 2015. Simultaneous improvement of solubility and permeability by fabricating binary glassy materials of talinolol with naringin: Solid state characterization, in-vivo in-situ evaluation. Eur J Pharm Sci. 78:234-44.
Tianjin Institute of Pharmaceutical Research Co Ltd. 2013. Co-amorphous system and preparation method. Available from: https://patents.google.com/patent/CN104415042A/en?oq=CN104415042A
Uppala, S., Sai Krishna Anand Vullendula, Dani Lakshman Yarlagadda, Swapnil Jayant Dengale. 2022. Exploring the utility of co-amorphous materials to concurrently improve the solubility and permeability of fexofenadine. Journal of Drug Delivery Science and Technology. 72: 103431.
Wang, R., Jiawei Han, Ai Jiang, Rong Huang, Tingming Fu, Lingchong Wang, Qin Zheng, Wen Li, Junsong Li. 2019. Involvement of metabolism-permeability in enhancing the oral bioavailability of curcumin in excipient-free solid dispersions co-formed with piperine. International Journal of Pharmaceutics. 561: 9-18,
Wiergowska G, Ludowicz D, Wdowiak K, Miklaszewski A, Lewandowska K, Cielecka-Piontek J. 2021. Combinations of freeze-dried amorphous vardenafil hydrochloride with saccharides as a way to enhance dissolution rate and permeability. Pharmaceuticals. 14(5):453.
Wuhan Yuan Zhu Pharmaceutical Technology Co Ltd. 2014. Baicalein-caffeine amorphous compound. Available from: https://patents.google.com/patent/CN103923049A/en?oq=CN103923049A
Yu D, Kan Z, Shan F, Zang J, Zhou J. 2020. Triple strategies to improve oral bioavailability by fabricating coamorphous forms of ursolic acid with piperine: enhancing water-solubility, permeability, and inhibiting cytochrome p450 isozymes. Mol Pharm. 17(12):4443-4462.